Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37214
Title: | The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. | Authors: | Brown A.J.;Mirzaee S.;Thein P.M. ;Nogic J.;Nerlekar N. ;Nasis A. | Institution: | (Mirzaee, Thein, Nogic, Nerlekar, Nasis, Brown) Monash Cardiovascular Research Centre, Monash Heart, Monash Health, Monash University, Melbourne, Australia | Issue Date: | 17-Oct-2018 | Copyright year: | 2018 | Publisher: | Elsevier Ltd | Place of publication: | United Kingdom | Publication information: | Journal of Clinical Lipidology. 12 (5) (pp 1133-1140.e15), 2018. Date of Publication: September - October 2018. | Journal: | Journal of Clinical Lipidology | Abstract: | Background: Current guidelines recommend an intensive lipid-lowering therapy to achieve the low-density lipoprotein cholesterol (LDL-C) target in patients with high risk of cardiovascular disease. Former studies suggested adding ezetimibe to statin therapy in the above setting may promote plaque changes; however, this effect has not been consistently reported. Method(s): Electronic searches were performed in MEDLINE, EMBASE, and Cochrane library on November 30, 2017 to identify prospective trials assessing the effects of combined ezetimibe and statin therapy versus statin therapy alone on atheroma volume using intravascular ultrasound. The effect size between treatment groups within individual studies was assessed by weighted mean difference (MD) using a random-effects model. Result(s): Eight studies were obtained for systematic review and 6 of them compromising total of 583 subjects that meet the criteria were meta-analyzed. There was a significant reduction from baseline to follow-up in total atheroma volume with an MD of -3.71 mm3 (95% confidence interval: -5.98 to -1.44, P <.001), whereas analysis for percent atheroma volume demonstrated weighted MD of - 0.77% (-1.68 to 0.14, P =.10). A substantial decrease in LDL-C was observed with MD -16.75 mg/dL (-20.89 to -12.60, P <.00001). Conclusion(s): The addition of ezetimibe to statin therapy is effective in reducing total atheroma volume assessed by intravascular ultrasound and also resulted in effective reduction of plasma LDL-C levels.Copyright © 2018 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.jacl.2018.06.001 | Link to associated publication: | Click here for full text options | PubMed URL: | 30318063 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30318063] | ISSN: | 1933-2874 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/37214 | Type: | Review | Subjects: | effect size follow up human *intravascular ultrasound meta analysis priority journal review systematic review therapy effect *ezetimibe/cb [Drug Combination] *ezetimibe/dt [Drug Therapy] *hydroxymethylglutaryl coenzyme A reductase inhibitor/dt [Drug Therapy] low density lipoprotein cholesterol/ec [Endogenous Compound] *hydroxymethylglutaryl coenzyme A reductase inhibitor/cb [Drug Combination] cholesterol blood level comparative study *coronary artery atherosclerosis/dt [Drug Therapy] atheroma therapy effect systematic review Review priority journal meta analysis *intravascular ultrasound human effect size *coronary artery atherosclerosis / *drug therapy comparative study cholesterol blood level atheroma follow up |
Type of Clinical Study or Trial: | Systematic review and/or meta-analysis |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.